Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hypoxia Inducible Factor (HIF)”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04736706
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,854
Large-scale testing (Phase 3)Study completedNCT02892149
What this trial is testing

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Who this might be right for
AnemiaDialysis-Dependent Chronic Kidney Disease
Akebia Therapeutics 3,554
Post-approval studies (Phase 4)Not Yet RecruitingNCT07162090
What this trial is testing

Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients

Who this might be right for
SarcopeniaAnemia Associated With Chronic Kidney Disease (CKD)Dialysis Patients
Tianjin Medical University General Hospital 60
Not applicableLooking for participantsNCT07136792
What this trial is testing

Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)

Who this might be right for
Renal Anemia of Chronic Kidney Disease
Guangdong Provincial People's Hospital 96
Early research (Phase 1)Ended earlyNCT01297530
What this trial is testing

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies

Who this might be right for
Neoplasms
Bayer 5
Not applicableStudy completedNCT01429467
What this trial is testing

Glucose Variability in Type 1 Diabetes and Its Effect on Factors That Influence New Vessel Formation

Who this might be right for
Type 1 Diabetes
University of Dundee 35
Not applicableStudy completedNCT00646555
What this trial is testing

Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis

Who this might be right for
Breast Neoplasms
National Cancer Institute (NCI) 300
Not applicableStudy completedNCT02163473
What this trial is testing

Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock

Who this might be right for
Sepsis
University of Florida 63
Early research (Phase 1)Study completedNCT01889823
What this trial is testing

Effects of Oxygen Status on Hypoxia Inducible Factor 1-α and Inflammation. A Pilot Proof of Principle Study.

Who this might be right for
HypoxiaHyperoxia
Radboud University Medical Center 20
Early research (Phase 1)Study completedNCT02299661
What this trial is testing

Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease

Who this might be right for
Chronic Renal DiseaseRenal Anemia
Daiichi Sankyo 31
Testing effectiveness (Phase 2)Study completedNCT02260193
What this trial is testing

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Who this might be right for
AnemiaEnd Stage Renal Disease
Akebia Therapeutics 94
Large-scale testing (Phase 3)Study completedNCT02648347
What this trial is testing

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Who this might be right for
AnemiaNon-Dialysis-Dependent Chronic Kidney Disease
Akebia Therapeutics 1,751
Early research (Phase 1)Study completedNCT04846920
What this trial is testing

Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 29
Post-approval studies (Phase 4)Study completedNCT06115421
What this trial is testing

Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients

Who this might be right for
Anemia in Dialysis-dependent CKD Patients
Alexandria University 72
Testing effectiveness (Phase 2)Study completedNCT01906489
What this trial is testing

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Who this might be right for
AnemiaChronic Kidney Disease
Akebia Therapeutics 210
Testing effectiveness (Phase 2)Ended earlyNCT03140722
What this trial is testing

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Who this might be right for
AnemiaDialysis-Dependent Chronic Kidney Disease
Akebia Therapeutics 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT05468697
What this trial is testing

Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 60
Large-scale testing (Phase 3)Study completedNCT02865850
What this trial is testing

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Who this might be right for
AnemiaDialysis-Dependent Chronic Kidney Disease
Akebia Therapeutics 369
Early research (Phase 1)Study completedNCT06919991
What this trial is testing

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

Who this might be right for
Healthy Participants
Arcus Biosciences, Inc. 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT03634540
What this trial is testing

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Who this might be right for
Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma (ccRCC)Kidney Cancer+6 more
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 118
Next Page